4-Nitro-2,3-dimethyl-benzamid | 90557-85-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Nitro-2,3-dimethyl-benzamid
• 英文别名: 2,3-Dimethyl-4-nitrobenzamide
• CAS: 90557-85-0
• 化学式: C₉H₁₀N₂O₃
• 分子量: 194.19
• InChiKey: CTFOWZPTUAPKAU-UHFFFAOYSA-N

物化性质

• 沸点：
  307.1±42.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  88.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Nitro-2,3-dimethyl-benzamid 在 硫酸 、 sodium nitrite 作用下， 生成 2,3-Dimethyl-4-nitro-benzoesaeure-methylester
  参考文献：
  名称：

  Vene,J. et al., Bulletin de la Societe Chimique de France, 1963, p. 1813 - 1817

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-二甲基-4-硝基苯胺 在 硫酸 、 水 、 双氧水 、 溶剂黄146 、 sodium hydroxide 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.75h， 生成 4-Nitro-2,3-dimethyl-benzamid
  参考文献：
  名称：

  CN116621704

  摘要：

  公开号：

文献信息

• [EN] SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINAZOLINE ET DE PYRIDO-PYRIMIDINE SUBSTITUÉES
  申请人：ENDO PHARMACEUTICALS INC

  公开号：WO2012058671A1

  公开（公告）日：2012-05-03

  The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新型的取代喹唑啉和吡啶并嘧啶化合物及其药用盐。还提供了制备这些化合物的方法。通过向患者投与一种或多种化合物的治疗有效量，这些化合物对于通过共同调节PI3K和/或mTOR活性来治疗与PI3K/AKT/mTOR通路失调相关的疾病是有效的。这些化合物具有双重PI3K/mTOR抑制剂的作用。这些化合物可用于治疗多种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS
  申请人：PHARMACIA & UPJOHN S.p.A.

  公开号：EP1124810A1

  公开（公告）日：2001-08-22
• THIAZOLYL-DIHYDRO-INDAZOLES
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2280982A1

  公开（公告）日：2011-02-09
• [EN] 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS<br/>[FR] DERIVES 2-AMINO-THIAZOLE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTITUMORAUX
  申请人：PHARMACIA & UPJOHN SPA

  公开号：WO2000026202A1

  公开（公告）日：2000-05-11

  Compounds which are 2-amino-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from i) straight or branched C1-C8 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; ii) C3-C6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain; R1 is an optionally substituted group selected from: i) straight or branched C1-C8 alkyl or C2-C6 alkenyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring; iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain; v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain; vi) an optionally protected amino acid residue; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.